Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Single-dose liposomal amphotericin B for visceral leishmaniasis in India.

Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.

N Engl J Med. 2010 Feb 11;362(6):504-12. doi: 10.1056/NEJMoa0903627.

2.

IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection.

Anderson CF, Stumhofer JS, Hunter CA, Sacks D.

J Immunol. 2009 Oct 1;183(7):4619-27. doi: 10.4049/jimmunol.0804024. Epub 2009 Sep 11.

3.

Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.

Vélez ID, Colmenares LM, Muñoz CA.

Rev Inst Med Trop Sao Paulo. 2009 Jul-Aug;51(4):231-6.

4.

Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process.

Okwor I, Liu D, Beverley SM, Uzonna JE.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13951-6. doi: 10.1073/pnas.0905184106. Epub 2009 Aug 6.

5.

What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis.

Maurer M, Dondji B, von Stebut E.

Med Microbiol Immunol. 2009 Aug;198(3):137-46. doi: 10.1007/s00430-009-0114-9. Epub 2009 Apr 25. Review.

PMID:
19396461
6.

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S.

Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.

7.

Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.

Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K.

Am J Trop Med Hyg. 2009 Apr;80(4):580-2.

PMID:
19346379
8.

Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion.

Pandrea I, Gaufin T, Brenchley JM, Gautam R, Monjure C, Gautam A, Coleman C, Lackner AA, Ribeiro RM, Douek DC, Apetrei C.

J Immunol. 2008 Nov 15;181(10):6687-91.

9.

Leishmaniases' burden of disease: ways forward for getting from speculation to reality.

Reithinger R.

PLoS Negl Trop Dis. 2008;2(10):e285. doi: 10.1371/journal.pntd.0000285. Epub 2008 Oct 29. No abstract available.

10.

FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo.

Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, Brouwer D, Barbour S, Kovalev GI, Unutmaz D, Su L.

Blood. 2008 Oct 1;112(7):2858-68. doi: 10.1182/blood-2008-03-145946. Epub 2008 Jun 10.

11.

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM.

Blood. 2008 Aug 1;112(3):610-8. doi: 10.1182/blood-2008-01-135319. Epub 2008 Jun 2.

12.

Interleukin-10 and the pathogenesis of human visceral leishmaniasis.

Nylén S, Sacks D.

Trends Immunol. 2007 Sep;28(9):378-84. Epub 2007 Aug 6. Review.

PMID:
17689290
14.

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C.

Blood. 2007 Nov 1;110(9):3192-201. Epub 2007 Jul 6.

15.

Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.

Phillips SM, Bhopale MK, Constantinescu CS, Ciric B, Hilliard B, Ventura E, Lavi E, Rostami A.

J Neurol Sci. 2007 Dec 15;263(1-2):59-69. Epub 2007 Jul 2.

PMID:
17603081
16.

T(H)1 cells control themselves by producing interleukin-10.

O'Garra A, Vieira P.

Nat Rev Immunol. 2007 Jun;7(6):425-8. Review.

PMID:
17525751
17.

Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis.

Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D.

J Exp Med. 2007 Apr 16;204(4):805-17. Epub 2007 Mar 26.

18.

Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.

Mahnke K, Schönfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, Enk AH.

Int J Cancer. 2007 Jun 15;120(12):2723-33.

19.

CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis.

Anderson CF, Oukka M, Kuchroo VJ, Sacks D.

J Exp Med. 2007 Feb 19;204(2):285-97. Epub 2007 Feb 5.

20.

Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy.

Bodas M, Jain N, Awasthi A, Martin S, Penke Loka RK, Dandekar D, Mitra D, Saha B.

J Immunol. 2006 Oct 1;177(7):4636-43.

Supplemental Content

Support Center